Chapter One — 1.1 Background to the Study

Immunization Coverage has increasingly attracted the attention of researchers, regulators, and practitioners concerned with disease prevalence. This growing interest reflects the recognition that immunization coverage does not operate in isolation, but interacts with a wider set of institutional and market conditions found within Selected Listed Manufacturing Firms in Nigeria.

Selected Listed Manufacturing Firms in Nigeria presents a useful setting for examining this relationship precisely because the conditions there — structural, regulatory, and behavioural — differ from those typically assumed in the broader literature, most of which draws on evidence from more developed economies.

1.2 Statement of the Problem

Despite a growing body of literature on immunization coverage, there remains limited consensus on the precise nature of its relationship with disease prevalence, particularly within Selected Listed Manufacturing Firms in Nigeria. Many organizations continue to make decisions about immunization coverage without a clear, evidence-based understanding of how those decisions ultimately affect disease prevalence. This gap between practice and empirical understanding is the central problem this study seeks to address.

1.3 Objectives of the Study

1. To examine the effect of Immunization Coverage on disease prevalence in Selected Listed Manufacturing Firms in Nigeria.
2. To assess the extent to which immunization coverage influences disease prevalence within the study area.
3. To identify the challenges associated with immunization coverage in relation to disease prevalence.
4. To recommend strategies for optimizing immunization coverage in order to improve disease prevalence.

1.4 Research Questions

1. What is the effect of immunization coverage on disease prevalence in Selected Listed Manufacturing Firms in Nigeria?
2. To what extent does immunization coverage influence disease prevalence within the study area?
3. What challenges are associated with immunization coverage in relation to disease prevalence?
4. What strategies can be adopted to optimize immunization coverage in order to improve disease prevalence?

1.5 Significance of the Study

This study is significant to a range of stakeholders. For policymakers and regulators, the findings offer evidence to guide the design of frameworks that support healthier outcomes around disease prevalence. For managers and practitioners within Selected Listed Manufacturing Firms in Nigeria, the study provides practical insight into how immunization coverage can be better managed. Finally, it contributes to the academic literature on public health by extending existing knowledge into a specific empirical context, and offers a reference point for future researchers.

1.6 Scope of the Study

The study is limited to an examination of Immunization Coverage and its relationship with disease prevalence within the context of Selected Listed Manufacturing Firms in Nigeria. It reflects a clearly defined scope of analysis and relies on data and perspectives available within that scope; generalizing the findings beyond this specific context should therefore be done with appropriate caution.